АВАнна Викторовна Власова

Анна Викторовна Власова

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Анна Викторовна Власова has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Local experience in adapting «SCAT 2025» scale for risk stratification of resistant pathogens and selection of initial empirical antimicrobial therapy in a multispecialty children’s hospital

    by A.V. Vlasova, V.V. Gorev, U.V. Lukash, E.V. Smirnova, N.N. Volkova, D.V. Gorokhov, А.а. Bystrova, O.YU. Brunova, S.I. Valieva, Т.а. Tenovskaya, et al.

    Objective. To develop and perform pilot prospective validation of a locally adapted pediatric version of the SCAT scale for risk stratification of resistant pathogens and justification of initial empirical antimicrobial therapy in hospitalized children in a multispecialty children’s hospital. Materials and Methods. Over the period from 15 December 2025 to 15 February 2026, a single-center prospective observational study was conducted at the Morozovskaya Children’s City Clinical Hospital. The study included two sequential phases: local adaptation of the SCAT scale for risk stratification of resistant pathogens to pediatric practice and pilot clinical validation of the adapted version. The adaptation was carried out considering the patient flow structure, prior antibacterial therapy, local microbiological data, and expert assessment. The validation phase sequentially enrolled 100 patients hospitalized in intensive care units of the Morozovskaya Children’s City Clinical Hospital who required initial empiric antimicrobial therapy. For each patient, the risk category was determined according to the reference version of the “SCAT 2025” scale and the version adapted for this children’s hospital, the “SCAT pediatric Morozovskaya” scale, and the recommended initial therapy according to the adapted scale was assessed. The primary endpoint was the proportion of cases with adequate choice of initial empirical antimicrobial therapy. Therapy was considered adequate if, based on the assigned risk category, in vitro activity corresponded to the clinically significant isolated pathogen upon subsequent microbiological verification. Secondary endpoints included the frequency of therapy escalation and de-escalation, and the consistency between the original and adapted versions of stratification. Results. This study included 100 patients. Local adaptation of the scale resulted in changes to 4 parameters and the addition of 9 risk-determining parameters, primarily related to comorbidity in children hospitalized in the following profiles: pediatric surgery, pediatric oncology, onco-hematology, and children at risk of invasive mycosis. Compared to the original pediatric version of SCAT, the adapted version changed the risk category for 30 (30%) patients. An adequate choice of initial empirical antimicrobial therapy was achieved in 97 (97%) cases. Therapy escalation due to insufficient initial coverage was required in 3 (3%) patients. The greatest clinical applicability of the adapted tool was noted in subgroups of children with congenital malformations, oncological and onco-hematological diseases, the presence of invasive devices, and the risk of invasive mycosis. Conclusions. The experience of the Morozovskaya Children’s City Clinical Hospital is presented based on the analysis of local data on the structure of patients in the medical care profiles, which allowed doctors to adapt the updated antibiotic stewardship «SCAT 2025» tool to the existing needs of «SCAT Children Morozovskaya», taking into account the specifics of informed decision-making process. The proposed «SCAT Children Morozovskaya» tool increases the accuracy of therapeutic strategies when prescribing antimicrobial drugs, which in turn contributes to improving treatment outcomes.

  • Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience

    by V.S. Lobanova, Yu.E. Martynenko, A.V. Vlasova, I.P. Vitkovskaya, T.N. Kekeeva, N.L. Pechatnikova, A.A. Chudaykina, N.A. Krasnoschekova, A.A. Rahalina, V.V. Zarubina, et al.

    Objective. To assess the efficacy and safety of onasemnogene abeparvovec (OA) in children with spinal muscular atrophy (SMA) treated between 2021 and 2025 at a Moscow regional rare disease referral center (Morozov Children’s City Clinical Hospital). Material and methods. This study included 20 children with a confirmed diagnosis of 5q spinal muscular atrophy (SMA). Safety was evaluated in all 20 patients for up to 3.5 years following treatment, with adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Efficacy was analyzed in 16 patients at 8 to 37 months post-injection. Motor function was assessed using the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), while general motor development was evaluated using the Hammersmith Infant Neurological Examination, Section 2 (HINE-2). Key motor milestones were compared to established World Health Organization (WHO) norms. Data was analyzed by stratifying patients into two groups: those identified through expanded newborn screening (Group 1) and those diagnosed via high-risk screening (Group 2). Results. In Group 1, the mean age at treatment initiation was 1.9 (1.4—2.8) months, with a mean weight of 4.8 (3.7—6.25) kg. In Group 2, the mean age at treatment was 14.8 (5.5—47) months, with a mean weight of 9 (6—13.7 )kg. Within one week post-OA administration, most patients (19/20) experienced clinical symptoms, including hyperthermia (Group 1: 8/9; Group 2: 10/11), increased regurgitation/vomiting (Group 1: 5/9; Group 2: 6/11), and decreased appetite/refusal to feed (Group 1: 3/9; Group 2: 9/11). These symptoms were more severe in Group 2, requiring intravenous and symptomatic therapy, nasogastric tube placement, and parenteral nutrition in some cases. Grade 1—2 thrombocytopenia (CTCAE v.5) was observed one week post-OA in three patients from Group 2. Elevated hepatic transaminases were observed in 16/20 children: Group 1 — 6/9 (66%), Group 2 — 10/11 (90%). In Group 1, all children experienced Grade 1 elevations (CTCAE v.5), while in Group 2, 6 children had Grade 1 elevations (54%), 2 had Grade 2 (18%), 1 had Grade 3 (9%), and 1 had Grade 4 (>20x ULN) (9%). Asymptomatic troponin I elevations were recorded in 6 children from Group 1 and 4 from Group 2. The median duration of prednisolone administration was 13 weeks (8—24) in Group 1 and 21 weeks (12—42) in Group 2. In Group 1, the mean CHOP INTEND score increased by 11.5 at 4 months, the HINE-2 score increased by 10.5 points at 4 months and 15.5 points at 6 months from baseline; all children achieved main motor milestones according to WHO norms. In Group 2, the mean CHOP INTEND score increased by 4 at 6 months and 7.2 points at 12 months from baseline; the HINE-2 score increased by 2.3 points at 6 months and 4.7 points at 12 months from baseline; five children improved their functional status, and 6/9 children acquired new motor skills. Conclusion. This study presents the findings of a long-term assessment of the efficacy and safety profile of drug OA in pediatric patients across various age groups and functional ability levels, including individuals identified through expanded newborn screening. Younger patients exhibited a significantly lower incidence of adverse events and demonstrated superior therapeutic efficacy. The majority of older children experienced either positive progression or stabilization of their condition, outcomes that were largely contingent upon their initial functional status and the duration of the pre-treatment waiting period.

  • Open Access

    Choosing a pharmacogenomic strategy for targeted therapy of cystic fibrosis: the story of one patient

    by A. V. Vlasova, E. E. Yakushina, I. R. Gaziev, O. I. Simonova, U. V. Lukash, D. A. Sychev

    Relevance. The study of pharmacokinetic and pharmacodynamic drug interactions involving components of targeted medications demonstrates the lack of available data and the significant need for research aimed at describing the likelihood, extent, and clinical impact of proposed drug interactions for individual patients and for the population of patients with cystic fibrosis. Objective. To describe a clinical case of a patient with cystic fibrosis F508del in the CFTR gene in combination with PIDS (Common Variable Immune Deficiency) a carrier of the potentially "problematic" CYP3A5 *3/*3 and SLCO1B1 *1/*5 genotypes for liver metabolism, with an assessment of the safety of the targeted therapy for cystic fibrosis. Materials and methods . For genetic analysis, the isolated DNA was examined using the iPLEX Pro PGx panel (Agena Bioscience) in the "VeriDose® Core Panel" modification, the patient revealed: P-glycoprotein (P-gp) gene ABCB1 (rs1045642) G/G, APOE E2/E3, CYP1A2*1A/*1F, CYP2B6*1/*1, CYP2C19*1/*1 , CYP3A4*1/*1 , CYP3A5*3/*3 , PNPLA5 (RS5764010) C/C and SLCO1B1*1/*5 . Results. The patient's biochemical abnormalities were clarified during the selection of a drug for targeted therapy of cystic fibrosis, as well as during the use and switching of targets. Clinically insignificant abnormalities in biochemical liver function parameters were not accompanied by clinical symptoms. Conclusion. Modern pharmacogenetic testing capabilities have made it possible to identify a potentially "problematic" combination of CYP3A *3/*3 and SLCO1B1 *1/*5 genotypes in a patient, which is associated with changes in drug metabolism in the liver. Therefore, the use of pharmacogenetic testing in patients with genetic diseases opens up opportunities for personalization and improvement of pharmacotherapy safety, allowing for the prevention or delay of organ dysfunction to enhance.

  • Promising directions for the use of intravenous fosfomycin in children

    by Vlasova A.V. Vlasova, Kameneva T.R. Kameneva, Yakovlev S.V. Yakovlev

  • Open Access

    Improving the Pharmacovigilance System in Medical Organisations as an Opportunity to Enhance the Quality of Pharmacotherapy

    by M. V. Zhuravleva, S. Yu. Serebrova, E. V. Kuznetsova, T. R. Kameneva, A. V. Vlasova, A. B. Prokofiev, E. Yu. Demchenkova

    INTRODUCTION. It is essential to monitor the efficacy and safety of medicinal products as part of post-marketing surveillance to identify, assess, and prevent adverse drug reactions (ADRs). The effectiveness of pharmacovigilance depends largely on healthcare professionals’ adherence to the requirements and timeframes for reporting information to regulatory authorities.AIM. This study aimed to identify and systematise the key aspects of pharmacovigilance through an analysis of experience in organising pharmacovigilance in Moscow-based healthcare institutions in 2018–2024 to determine the focus areas for implementing, monitoring, and improving the pharmacovigilance system operating in medical organisations.DISCUSSION. The significance of pharmacovigilance systems and the need for their continuous improvement are underpinned by experience in establishing pharmacovigilance databases, including the global VigiBase database, the European Union’s EudraVigilance database, and the Eurasian Economic Union’s database. The main pharmacovigilance tools include active surveillance and collection of unsolicited/solicited reports of suspected ADRs. The Russian Federal Service for Surveillance in Healthcare (Roszdravnadzor) has developed clear operational criteria for pharmacovigilance in medical organisations. These criteria require that medical organisations should have in-house regulations for collecting, registering, and reporting data on ADRs to Roszdravnadzor, appointing qualified persons responsible for pharmacovigilance, and obtaining access to the Pharmacovigilance database of Roszdravnadzor’s Automated Information System. This article provides a detailed description of tools for establishing an effective pharmacovigilance system in a medical organisation, as well as the focus areas for organising pharmacovigilance in medical organisations, identified by analysing the experience of a territorial entity of the Russian Federation.CONCLUSIONS. To improve the effectiveness of pharmacovigilance in medical organisations, it is necessary to ensure the quality, integrity, and completeness of data submitted in spontaneous ADR reports. Spontaneous reporting should be supplemented with active surveillance methods, including the Global Trigger Tool. The current pharmacovigilance system in Moscow demonstrates a steady increase in reporting ADRs to Roszdravnadzor.


  • Algorithm for auditing the rationality of clinical practice of using antibiotics in hospitals for children

    by Vlasova A.V. Vlasova, Smirnova E.V. Smirnova, Kulichenko T.V. Kulichenko, Sychev D.A. Sychev, Moscow Morozov Children’s City Clinical Hospital, Moscow Russian Medical Academy Of Continuous Professional Education


  • Open Access

    The safety of medicinal prescriptions in children in critical conditions: antibiotics are in focus

    by A. V. Vlasova, T. V. Kulichenko, D. A. Sychev

    Introduction. The relevance of the introduction of a system for evaluating medicinal prescriptions to control the safety of the use of antibiotics and concomitant therapy is due to the emergence of electronic medical records in multidisciplinary children’s hospitals.Aim. To assess the potential risks of adverse reactions to antibiotics using an implemented retrospective cohort analysis of antimicrobial drug prescriptions in critically ill children.Materials and methods. The analysis of the effect of antibiotic prescriptions on the potential risk of HP in the development of a critical condition in children was performed as part of a prospective observational study at the Morozov Children’s City Clinical Hospital from 02/01/2020 to 09/01/2021 in 100 children aged 0 to 17 years. To evaluate the prescribing lists, a twostage retrospective cohort analysis method was used to assess the potential risks of HP for antibiotics in the development of a critical condition in children with nosocomial infection. The patients were divided into 2 cohorts in 2 stages: at stage 1, an analysis was performed in 1 cohort “outcome HP+” of 30 children with HP on antibiotics and 2 cohort “outcome HP–” of 70 children without HP on antibiotics. At stage 2, an analysis was carried out in the same cohorts with an additional sampling criterion “availability of concomitant therapy” for 40 patients.Results and discussion. The possibilities of taking into account additional potential risks of HP for antibiotics when making an appointment list in children with nosocomial infection with the development of a critical condition are shown. In the group of children receiving concomitant therapy, the highest relative risk of developing HP for antibiotics was revealed when using tigecycline (OR 7.24; 95% CI 0.64–8.21) and meropenem (OR 1.84; 95% CI 1.01–3.36).Conclusion. The study shows the possibilities and prospects for the development of a risk-based approach when choosing combinations of antimicrobial drugs when making an appointment sheet based on an electronic medical record of an inpatient.

  • Open Access

    Pharmacogenomic Predictors of Antibiotic-Associated Drug-Induced Liver Injury in Critically Ill Children: Observational Study Results

    by A. V. Vlasova, Yu. F. Shubina, I. R. Gaziev, D. A. Sychev

    INTRODUCTION. The pathogenesis of antibiotic-associated drug-induced liver injury (DILI) in children has not been fully elucidated to date. Certain genotypes in patients increase the probability of developing DILI. Therefore, the identification of pharmacogenetic markers associated with DILI in children is essential.АIM. This study aimed to identify pharmacogenetic biomarkers of new-onset DILI associated with tigecycline and meropenem in children.MATERIALS AND METHODS. This prospective observational study was conducted in the Morozov Children’s City Clinical Hospital from 1 February 2020 to 1 September 2021. The study analysed the incidence and types of antibiotic-associated adverse drug reactions (ADRs) in 100 critically ill children aged 0 to 17 years (44 boys and 56 girls). Pharmacogenetic testing was performed in children with ADRs (n=30) to identify potential mechanisms involved in the development of their ADRs. The authors isolated and tested DNA from buccal epithelium swabs using the Agena Bioscience iPLEX® PGx Pro-based VeriDose® Core Panel covering 68 single nucleotide polymorphisms (SNPs) or short insertions and deletions (INDELs) and 5 copy number variants (CNVs).RESULTS. The odds of developing DILI associated with meropenem and tigecycline were higher in carriers of the homozygous cytochrome genotype CYP3A5*3/*3 (OR: 12.6; 95% CI: 1.9–79.4, r=6.54, p=0.011) than in patients with the heterozygous genotype CYP3A5*1A/*3. The odds were even higher in patients not carrying the CYP3A5*1A/*3 genotype (OR: 17.14; 95% CI: 1.79–16.3, r=6.24, p=0.013). The detection of the CYP3A5*3/*3 ge­notype had a prognostic accuracy of 76.7%, a sensitivity of 82%, and a specificity of 74% in predicting the risk of DILI associated with meropenem and tigecycline. Moreover, children with DILI carried the heterozygous ge­notype SLCO1B1*1/*5 (rs4149056 polymorphism) more often than children with other adverse reactions ­associated with meropenem and tigecycline (r=9.8, p=0.002).CONCLUSION. The results of this study prove the prognostic significance of the homozygous cytochrome genotype CYP3A*3/*3 as an indicator of a potential risk for developing DILI associated with meropenem and tigecycline in children in critical conditions.The study was registered at ClinicalTrials.gov under No. NCT04141657 on 24 October 2019.


  • Open Access

    WHO AWaRe Method for Analysis of Clinical Practice of Antimicrobial Therapy in Children's Multidisciplinary Hospitals in Russia

    by A. V. Vlasova, T. V. Kulichenko, E. V. Smirnova, N. N. Volkova, L. V. Dymnova, D. A. Sychev

    The new AWaRe classification proposed by WHO for assessing the clinical practice of using antibiotics in adults in 2017 was adapted for children's hospitals in 2019, due to the update of the categorization of antimicrobials, and showed effec- tiveness for assessing the rationality of antimicrobials use in children's hospitals in WHO-participating countries in the observation protocol GARPEC. In this retrospective pharmacoepidemiological study, we assessed the rationality of antibiotic consumption in multidisciplinary hospitals in the subjects of the Russian Federation with a pediatric profile. An observational multicenter study of antibiotic consumption was carried out in the constituent entities of the Russian Federation (N=9). Consumption assessment was carried out using the AWaRe method, based on DDD analysis and the WHO list of essential antibiotics for children by groups: «Access» (green), «Watch» (yellow) and «Reserve»(red). The quantitative indicator «the number of days of therapy in the ATC group J01 Antibacterial drugs for systemic use» in the established standardized dose per 100 patient days in the pediatric profile in level III hospitals in 9 regions of Russia for 2021 was 214.93. On average, each of the hospitalized pediatric children received at least two antibiotics during the period of hospital treatment in 2021 in Russia. On average, in Russia, based on the results from 9 constituent entities of the Russian Federation, drugs in the «Admission» category were 44.24%, «Control» — 49.23%, «Reserve» — 0.88%. When categorizing according to WHO2019, negative characteristics were identified — either excessive use of cefazolin and amikacin in the «Access» category, or the predominance of drugs with antipseudomonas activity, ceftazidime and cefepime, in the «Watch» groups. A positive and more balanced version of the structure of antibiotic consumption in multidisciplinary children's hospitals was identified in Moscow («Access» — 37.3%, «Watch» — 59.29%, «Reserve» — 3.41%), in the Republic of Mari El («Access» — 30.28%, «Watch» — 69.42%, «Reserve» — 0.30%) and in the Republic of Khakassia («Access» — 30.95%, «Watch» — 67.39%, «Reserve» — 1.66%). Thus, «Access» (green), the main indicator of the assessment category of antibiotic consumption in children, did not reach 60% in 2021 in any of the multidisciplinary children's hospitals in Russia presented in this study, which was proposed as a target indicator for achieving rational consumption according to WHO. The results of this study showed the problems of irrational use of antibiotics: insufficient use of oral dosage forms in children, excessive use of aminoglycosides, unjustified switching to combination antimicrobial therapy with antibiotics of the «Reserve» group in multidisciplinary children's hospitals in Russia.